N/A N=7,387 Increasing Optimal Use of HPV Vaccination in Primary Care
Human Papillomavirus Vaccines
Primary: Initiation of the HPV Vaccine 2-dose Series. — 1723; 1219 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma
Refractory Large B-cell Lymphoma
Primary: Complete Response (CR) Rate Per the International Working Group (IWG) Lugano Classification as Determined by Study Investigators — 73 percentage of participants
Phase 3 N=1,148 A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Depressive Disorder, Treatment-Resistant
Primary: Change From Study Baseline in Computerized Cognitive Battery Domain Score: Detection Test (DET) Score — 0.0218; -0.0065 log10 msec
N/A N=46 Development of Technologies to Increase In-Seat Movement to Prevent Sitting-Acquired Pressure Injuries in Wheelchair Users
Pressure Ulcer · Pressure Injury · Wheelchair
Primary: Normalized Weight Shift Frequency (Weight Shifts/Hour) — 2.41; 2.38 normalized weight shifts per hour
Phase 1 N=12 Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics
Pulmonary Disease, Chronic Obstructive
Primary: Part A, Cohort-1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 6 Participants
Phase 1 N=66 A Study of Injections of LY3074828 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3074828 — 9.19; 8.19 microgram/milliliter (ug/mL)
Phase 1 N=35 A Bioequivalence Study of a New Paracetamol Oral Suspension 24mg/ml Compared to the Marketed Paracetamol Oral Suspension (Panadol Baby and Infant 24mg/ml) in Healthy Adult Subjects
Pain
Primary: The Area Under the Plasma Concentration [AUC] Versus Time Curve Calculated From Time Zero to the Last Measurable Sampling Time Point (Tlast) (AUC [0-tlast]) — 47.18…
N/A N=235 Type 2 Diabetes Exemplar: A Remote Care Service for North West London
Type 2 Diabetes Mellitus
Primary: % Participants Downloading Huma App — 95; 0 Participants
Phase 2 N=50 ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Cancer · Prostate Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events — 10; 1; 2; 37 Participants
N/A N=234 Working to Implement and Sustain Digital Outcome Measures
Implementation · Behavioral Symptoms
Primary: Percentage Fidelity to the OQ-A System Experienced by the Youth (0-100%) — 23.1; 3.4 percentage fidelity achieved — p=.014
Phase 3 N=331 Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery
Pain
Primary: Total Opioid Administered — 4.0; 6.0 Morphine Milligram Equivalents
Phase 2 N=6 A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease
Crohn Disease
Primary: The Total Number of Deregulated Genes at Week 4 — 0; 0 Deregulated genes
Phase 1 N=31 Maribavir Food-Effect Study in Healthy Adults Participants
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of Maribavir — 17.8; 13.4; 12.7 microgram per milliliter (mcg/mL)
N/A N=33 Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
Metastatic Breast Cancer · Breast Neoplasms
Primary: Time to Treatment Failure (TTF) for Talazoparib — 5.5 Months
N/A N=299 Integrating DR Into Mainstream Health System in Bangladesh
Diabetic Retinopathy
Primary: Number of Participants Who Had Successful Referrals — 92; 44 Participants — p=<0.001